Please assess the completion status of the following clinical trial:

Trial Title: C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 yrs of age; recipient of ECD/DCD/ECD\&DCD with risk index 3-8 for DGF based on specific criteria~* recipient who are ABO compatible with donor allograft~* pretransplant with meningococcal vaccination~* understand and sign a written consent prior to any study specific procedure.~Risk index (minimum 3- maximum 8):~DGF scale: Donor Age (\<40yr = 0, 41-49yr = 1, 50-54yr = 2, 55-59yr = 3, \>60yr=6), Cold Ischemia Time (0-12= 0, 13-18=1, 19-24=2, 24-30=3, 31-36=4, \>37=6; Recipient Race (nonblack = 0, black =1); Donor death due to Cerebrovascular Accident (CVA) (donor age \<50yrs = 0, donor age \>50yrs = 3).~Exclusion Criteria:~* patients with known prothrombotic disorder (e.g. factor V leiden)~* history of thrombosis or hypercoagulable state excluding access clotting~* history of administration of C1INH containing products or recombinant C1INH within 15 days prior to study entry~* patients with known contraindication to treatment with C1INH~* patients with abnormal coagulation function (INR \>2, partial thromboplastin time (PTT) \> 50, platelets \<80,000)~* who are not on anti-coagulation~* patients with known active presence of malignancies~* Polymerase chain reaction (PCR) positive for hep B/hep C/or HIV~* preemptive kidney transplantation recipient~* recipients of multi-organ transplants (kidney and any other organ)~* recipients of kidney allograft from DD who: cold ischemia time (CIT) \<18h, terminal serum creatinine \</= 1mg/dl, recipient of kidney allograft that was on pump preservation for any period prior to transplantation, recipient of kidney allograft from a living donor, female subject who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- C1-Inhibitor (Berinert) (Human) (C1INH) (Type: EXPERIMENTAL): 35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
- Normal Saline (Type: PLACEBO_COMPARATOR): 35 patients will receive placebo in addition to standard of care immunosuppressive therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).